Treatment of adults with locally advanced or metastatic urothelial carcinoma (bladder cancer) with susceptible FGFR2 or FGFR3 genetic alterations, confirmed by an approved diagnostic test.
Usually used after progression following at least one prior line of platinum-containing chemotherapy.
⚙️ Mechanism of Action
Erdafitinib is an oral FGFR kinase inhibitor.
It works by blocking the activity of FGFR2 and FGFR3, which are involved in tumor cell proliferation and survival.
By inhibiting these pathways, it slows or stops the growth of cancer cells with FGFR mutations or fusions.
📈 Pharmacokinetics
Absorption: Rapid, peak concentration ~2–4 hours
Bioavailability: ~40–50%
Distribution: Extensive, protein binding ~99%
Metabolism: Primarily by CYP2C9, CYP3A4 enzymes
Elimination: Half-life ~50 hours; excreted mostly in feces
💊 Dosage and Administration
Typical starting dose: 8 mg once daily
Dose adjustments based on phosphate levels and patient tolerance